Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRNXNASDAQ:DAWNNASDAQ:PTGXNASDAQ:SRRK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRNXCrinetics Pharmaceuticals$28.54-0.8%$31.44$24.10▼$62.53$2.67B0.28820,454 shs286,951 shsDAWNDay One Biopharmaceuticals$6.58+1.2%$6.77$6.08▼$16.76$663.40M-1.291.14 million shs673,231 shsPTGXProtagonist Therapeutics$50.37-8.9%$48.97$32.50▼$60.60$3.10B2.25892,097 shs970,847 shsSRRKScholar Rock$33.95-4.2%$32.23$6.76▼$46.98$3.20B0.281.29 million shs965,798 shs13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRNXCrinetics Pharmaceuticals-4.01%-3.84%-5.98%-6.07%-35.79%DAWNDay One Biopharmaceuticals+0.46%+0.31%+1.72%-14.59%-52.83%PTGXProtagonist Therapeutics-0.75%+3.58%+16.90%+17.90%+59.51%SRRKScholar Rock-1.09%+6.43%+21.59%+17.83%+325.21%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRNXCrinetics Pharmaceuticals3.5599 of 5 stars3.50.00.03.72.52.50.0DAWNDay One Biopharmaceuticals2.0895 of 5 stars3.62.00.00.01.52.50.0PTGXProtagonist Therapeutics1.7434 of 5 stars3.51.00.00.01.42.50.0SRRKScholar Rock3.6737 of 5 stars2.60.00.04.43.03.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRNXCrinetics Pharmaceuticals 2.91Moderate Buy$74.56161.24% UpsideDAWNDay One Biopharmaceuticals 3.13Buy$30.57364.96% UpsidePTGXProtagonist Therapeutics 3.00Buy$66.1031.23% UpsideSRRKScholar Rock 3.14Buy$42.6725.69% UpsideCurrent Analyst Ratings BreakdownLatest DAWN, CRNX, SRRK, and PTGX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/27/2025CRNXCrinetics PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$81.006/18/2025SRRKScholar RockWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$50.006/17/2025PTGXProtagonist TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$72.006/3/2025PTGXProtagonist TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$80.006/3/2025SRRKScholar RockLifesci CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/19/2025PTGXProtagonist TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$80.00 ➝ $80.005/14/2025SRRKScholar RockWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$50.005/7/2025DAWNDay One BiopharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$25.005/7/2025DAWNDay One BiopharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$30.00 ➝ $27.004/10/2025PTGXProtagonist TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$80.00 ➝ $80.004/3/2025DAWNDay One BiopharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$36.00 ➝ $36.00(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRNXCrinetics Pharmaceuticals$1.04M2,569.33N/AN/A$14.29 per share2.00DAWNDay One Biopharmaceuticals$131.16M5.08N/AN/A$4.99 per share1.32PTGXProtagonist Therapeutics$434.43M7.19$4.08 per share12.33$11.33 per share4.45SRRKScholar Rock$33.19M97.11N/AN/A$3.94 per share8.62Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRNXCrinetics Pharmaceuticals-$298.41M-$3.82N/AN/AN/AN/A-30.95%-28.12%8/6/2025 (Estimated)DAWNDay One Biopharmaceuticals-$95.50M-$0.71N/AN/AN/A-42.66%-14.98%-13.04%7/8/2025 (Estimated)PTGXProtagonist Therapeutics$275.19M$0.7566.78N/AN/A27.04%9.22%8.31%8/5/2025 (Estimated)SRRKScholar Rock-$246.29M-$2.53N/AN/AN/AN/A-118.22%-82.01%8/6/2025 (Estimated)Latest DAWN, CRNX, SRRK, and PTGX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/29/2025Q2 2025DAWNDay One Biopharmaceuticals-$0.35N/AN/AN/A$35.55 millionN/A5/14/2025Q1 2025SRRKScholar Rock-$0.63-$0.67-$0.04-$0.67N/AN/A5/8/2025Q1 2025CRNXCrinetics Pharmaceuticals-$0.99-$1.04-$0.05-$1.04$0.10 million$0.36 million5/6/2025Q1 2025DAWNDay One Biopharmaceuticals-$0.46-$0.35+$0.11-$0.35$30.28 million$30.76 million5/6/2025Q1 2025PTGXProtagonist Therapeutics-$0.50-$0.19+$0.31-$0.19$30.44 million$28.32 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRNXCrinetics PharmaceuticalsN/AN/AN/AN/AN/ADAWNDay One BiopharmaceuticalsN/AN/AN/AN/AN/APTGXProtagonist TherapeuticsN/AN/AN/AN/AN/ASRRKScholar RockN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRNXCrinetics PharmaceuticalsN/A22.5322.53DAWNDay One BiopharmaceuticalsN/A10.6210.55PTGXProtagonist TherapeuticsN/A17.2517.26SRRKScholar Rock0.1610.2510.25Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRNXCrinetics Pharmaceuticals98.51%DAWNDay One Biopharmaceuticals87.95%PTGXProtagonist Therapeutics98.63%SRRKScholar Rock91.08%Insider OwnershipCompanyInsider OwnershipCRNXCrinetics Pharmaceuticals6.00%DAWNDay One Biopharmaceuticals6.20%PTGXProtagonist Therapeutics4.90%SRRKScholar Rock13.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRNXCrinetics Pharmaceuticals21093.63 million88.01 millionOptionableDAWNDay One Biopharmaceuticals60101.36 million95.08 millionOptionablePTGXProtagonist Therapeutics12061.98 million58.95 millionOptionableSRRKScholar Rock14094.95 million82.32 millionOptionableDAWN, CRNX, SRRK, and PTGX HeadlinesRecent News About These CompaniesJeffrey S. Flier Sells 11,136 Shares of Scholar Rock Holding Corporation (NASDAQ:SRRK) StockJune 26, 2025 | insidertrades.comJeffrey S. Flier Sells 11,136 Shares of Scholar Rock Holding Corporation (NASDAQ:SRRK) StockJune 25, 2025 | marketbeat.comInsider Selling: Scholar Rock Holding Corporation (NASDAQ:SRRK) Director Sells 20,316 Shares of StockJune 25, 2025 | marketbeat.comScholar Rock (NASDAQ:SRRK) Shares Up 5.2% - Time to Buy?June 25, 2025 | marketbeat.comScholar Rock Holding Corp. (SRRK) Stock Price Today - WSJJune 24, 2025 | wsj.comScholar Rock Holding Corp News (SRRK) - Investing.comJune 24, 2025 | investing.comScholar Rock CEO on its drug that could preserve muscle in weight-loss drug usersJune 24, 2025 | youtube.comYScholar Rock: EMBRAZE Results Drive The Stock HigherJune 23, 2025 | seekingalpha.comScholar Rock (NASDAQ:SRRK) Trading Down 5.7% - Time to Sell?June 22, 2025 | americanbankingnews.comScholar Rock Holding Corporation (NASDAQ:SRRK) Receives Consensus Recommendation of "Buy" from BrokeragesJune 21, 2025 | americanbankingnews.comScholar Rock Holding Corporation (NASDAQ:SRRK) Receives Consensus Recommendation of "Buy" from AnalystsJune 21, 2025 | marketbeat.comScholar Rock (NASDAQ:SRRK) Shares Down 5.7% - Should You Sell?June 20, 2025 | marketbeat.comScholar Rock (SRRK) Jumps 16.6% After Successful Weight Loss Drug TrialJune 19, 2025 | insidermonkey.comScholar Rock data show promise for muscle-preserving combo with ZepboundJune 19, 2025 | thepharmaletter.comTScholar Rock (NASDAQ:SRRK) Receives Outperform Rating from WedbushJune 18, 2025 | marketbeat.comScholar Rock says its drug preserved lean mass in patients taking ZepoundJune 18, 2025 | statnews.comSScholar Rock Jumps on Weight Loss Data for Zepbound/Repurposed Antibody ComboJune 18, 2025 | biospace.comBScholar Rock's SMA drug helps weight loss patients on Zepbound retain muscle in phase 2 trialJune 18, 2025 | fiercebiotech.comFScholar Rock stock soars after drug shows promise in preserving lean mass during weight lossJune 18, 2025 | au.investing.comScholar Rock lead asset causes higher quality weight loss with Lilly’s obesity drugJune 18, 2025 | msn.comScholar Rock Stock Soars on Biopharma Firm's Weight-Loss Drug Trial ResultsJune 18, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDAWN, CRNX, SRRK, and PTGX Company DescriptionsCrinetics Pharmaceuticals NASDAQ:CRNX$28.54 -0.22 (-0.77%) As of 03:24 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.Day One Biopharmaceuticals NASDAQ:DAWN$6.56 +0.07 (+1.00%) As of 03:24 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.Protagonist Therapeutics NASDAQ:PTGX$50.37 -4.90 (-8.87%) As of 03:24 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.Scholar Rock NASDAQ:SRRK$33.94 -1.48 (-4.16%) As of 03:24 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 2 Reasons to Buy Trade Desk Stock Now and 1 Warning Sign 2 Under the Radar Space & Defense Stocks With Huge Potential Palantir’s $100M Nuclear OS Pact Boosts Bullish Case Joby Stock Soars as Piloted Flights in Dubai Signal a New Era Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500 S&P 500 All-Time Highs: 5 Catalysts Driving It Higher The Top Insider Sells From Q2: Buy, Sell, or Hold? 5 High-Yielding ETFs to Buy and Hold Forever Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
